{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:43:13Z","timestamp":1692906193834},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00108-023-01570-6","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T13:02:41Z","timestamp":1691586161000},"page":"848-854","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neurologische Manifestationen der ATTR-Amyloidose","Neurological manifestations of ATTR amyloidosis"],"prefix":"10.1007","volume":"64","author":[{"given":"Helena F.","family":"Pernice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"12","key":"1570_CR1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve\u00a0V, Said\u00a0G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10(12):1086\u20131097","journal-title":"Lancet Neurol"},{"issue":"7","key":"1570_CR2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.36.7.900","volume":"36","author":"J Herbert","year":"1986","unstructured":"Herbert\u00a0J et al (1986) Transthyretin: a\u00a0choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology 36(7):900\u2013911","journal-title":"Neurology"},{"issue":"6","key":"1570_CR3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jnc.15233","volume":"156","author":"MF Dohrn","year":"2021","unstructured":"Dohrn\u00a0MF et al (2021) Targeting transthyretin\u2014mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. J\u00a0Neurochem 156(6):802\u2013818","journal-title":"J Neurochem"},{"issue":"2","key":"1570_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000115544","volume":"22","author":"B Weisner","year":"1983","unstructured":"Weisner\u00a0B, Roethig\u00a0HJ (1983) The concentration of prealbumin in cerebrospinal fluid (CSF), indicator of CSF circulation disorders. Eur Neurol 22(2):96\u2013105","journal-title":"Eur Neurol"},{"issue":"36","key":"1570_CR5","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","volume":"31","author":"W Colon","year":"1992","unstructured":"Colon\u00a0W, Kelly\u00a0JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31(36):8654\u20138660","journal-title":"Biochemistry"},{"issue":"4","key":"1570_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr\u00a0OB, Lundgren\u00a0E, Westermark\u00a0P (2017) One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J\u00a0Intern Med 281(4):337\u2013347","journal-title":"J Intern Med"},{"issue":"1","key":"1570_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD et\u00a0al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"1570_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D et\u00a0al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"12","key":"1570_CR9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","volume":"108","author":"FAD Siepen","year":"2019","unstructured":"Siepen\u00a0FAD et\u00a0al (2019) Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 108(12):1324\u20131330","journal-title":"Clin Res Cardiol"},{"key":"1570_CR10","unstructured":"Mutations in hereditary amyloidosis. http:\/\/amyloidosismutations.com\/. Zugegriffen: 25. Jan. 2023"},{"key":"1570_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0","author":"D Adams","year":"2020","unstructured":"Adams D et al (2020) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J Neurol"},{"key":"1570_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2046557","author":"MC Kaku","year":"2022","unstructured":"Kaku MC et al (2022) Neurological manifestations of hereditary transthyretin amyloidosis: a\u00a0focus on diagnostic delays. Amyloid. https:\/\/doi.org\/10.1080\/13506129.2022.2046557","journal-title":"Amyloid"},{"issue":"1","key":"1570_CR13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","volume":"3","author":"MF Dohrn","year":"2021","unstructured":"Dohrn\u00a0MF et al (2021) Are we creating a\u00a0new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurol Res Pract 3(1):57","journal-title":"Neurol Res Pract"},{"issue":"2","key":"1570_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jns.12451","volume":"26","author":"S Tozza","year":"2021","unstructured":"Tozza\u00a0S et\u00a0al (2021) The neuropathy in hereditary transthyretin amyloidosis: A narrative review. J\u00a0Peripher Nerv Syst 26(2):155\u2013159","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"1570_CR15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acn3.51636","volume":"9","author":"R Freeman","year":"2022","unstructured":"Freeman\u00a0R et\u00a0al (2022) Cutaneous amyloid is a\u00a0biomarker in early ATTRv neuropathy and progresses across disease stages. Ann Clin Transl Neurol 9(9):1370\u20131383","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl 2","key":"1570_CR16","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3949\/ccjm.76.s2.08","volume":"76","author":"RW Shields Jr","year":"2009","unstructured":"Shields\u00a0RW Jr (2009) Heart rate variability with deep breathing as a\u00a0clinical test of cardiovagal function. Cleve Clin J Med 76(Suppl 2):S37\u2013S40","journal-title":"Cleve Clin J Med"},{"key":"1570_CR17","unstructured":"Coutinho\u00a0PM et\u00a0al (1980) Forty years of experience with type\u00a0I amyloid neuropathy. Review of 483 cases. Excerpta Medica, Amsterdam"},{"issue":"1","key":"1570_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0022-510X(93)90025-T","volume":"120","author":"Z Simmons","year":"1993","unstructured":"Simmons\u00a0Z et\u00a0al (1993) Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J\u00a0Neurol Sci 120(1):60\u201363","journal-title":"J Neurol Sci"},{"issue":"5","key":"1570_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/NRL.0000000000000337","volume":"26","author":"Q Qin","year":"2021","unstructured":"Qin\u00a0Q et\u00a0al (2021) Current review of leptomeningeal amyloidosis associated with transthyretin mutations. Neurologist 26(5):189\u2013195","journal-title":"Neurologist"},{"issue":"4","key":"1570_CR20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3233\/JND-200542","volume":"7","author":"F Kleefeld","year":"2020","unstructured":"Kleefeld\u00a0F et al (2020) Familial oculo-leptomeningeal transthyretin amyloidosis caused by leu55Arg mutation. J\u00a0Neuromuscul Dis 7(4):515\u2013519","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"1570_CR21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2021.2014448","volume":"29","author":"F Kleefeld","year":"2022","unstructured":"Kleefeld\u00a0F et\u00a0al (2022) Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Amyloid 29(2):92\u2013101","journal-title":"Amyloid"},{"issue":"1","key":"1570_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2021.1976751","volume":"29","author":"A Papagianni","year":"2022","unstructured":"Papagianni\u00a0A et al (2022) Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid 29(1):14\u201322","journal-title":"Amyloid"},{"issue":"3","key":"1570_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","volume":"25","author":"F Wajnsztajn Yungher","year":"2020","unstructured":"Wajnsztajn Yungher\u00a0F et\u00a0al (2020) Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J\u00a0Peripher Nerv Syst 25(3):265\u2013272","journal-title":"J Peripher Nerv Syst"},{"key":"1570_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13222","author":"P Eldhagen","year":"2020","unstructured":"Eldhagen P et al (2020) Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13222","journal-title":"J Intern Med"},{"issue":"3","key":"1570_CR25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/13506129.2022.2043270","volume":"29","author":"FA Barroso","year":"2022","unstructured":"Barroso\u00a0FA et\u00a0al (2022) Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid 29(3):175\u2013183","journal-title":"Amyloid"},{"key":"1570_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09962-6","author":"MF Dohrn","year":"2020","unstructured":"Dohrn MF et al (2020) Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German\/Austrian position and review of the literature. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09962-6","journal-title":"J Neurol"},{"issue":"11","key":"1570_CR27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"8","key":"1570_CR28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/a-0649-0724","volume":"45","author":"E Hund","year":"2018","unstructured":"Hund\u00a0E et\u00a0al (2018) Transthyretin amyloidosis (ATTR amyloidosis): recommendations for the management in Germany and Austria recommendations of the German society of amyloid diseases. Akt Neurol 45(8):605\u2013616","journal-title":"Akt Neurol"},{"issue":"2","key":"1570_CR29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","volume":"37","author":"A Ioannou","year":"2023","unstructured":"Ioannou\u00a0A, Fontana\u00a0M, Gillmore\u00a0JD (2023) RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs 37(2):127\u2013142","journal-title":"BioDrugs"},{"issue":"8","key":"1570_CR30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho\u00a0T et\u00a0al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy a randomized, controlled trial. Neurology 79(8):785\u2013792","journal-title":"Neurology"},{"issue":"3","key":"1570_CR31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz\u00a0M et al (2016) Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 23(3):178\u2013183","journal-title":"Amyloid"},{"key":"1570_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","author":"C Monteiro","year":"2019","unstructured":"Monteiro C et al (2019) Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.126526","journal-title":"JCI Insight"},{"issue":"6","key":"1570_CR33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini\u00a0G et al (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J\u00a0Cardiovasc Transl Res 6(6):1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"issue":"8853","key":"1570_CR34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren\u00a0G et\u00a0al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341(8853):1113\u20131116","journal-title":"Lancet"},{"issue":"9","key":"1570_CR35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-199511150-00009","volume":"60","author":"OB Suhr","year":"1995","unstructured":"Suhr\u00a0OB et al (1995) Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 60(9):933\u2013938","journal-title":"Transplantation"},{"issue":"9","key":"1570_CR36","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon\u00a0BG et\u00a0al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847\u20131854","journal-title":"Transplantation"},{"issue":"12","key":"1570_CR37","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/lt.22174","volume":"16","author":"L Llado","year":"2010","unstructured":"Llado\u00a0L et\u00a0al (2010) Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 16(12):1386\u20131392","journal-title":"Liver Transpl"},{"issue":"4","key":"1570_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","volume":"14","author":"JJ Liepnieks","year":"2007","unstructured":"Liepnieks\u00a0JJ, Benson\u00a0MD (2007) Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 14(4):277\u2013282","journal-title":"Amyloid"},{"issue":"4","key":"1570_CR39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","volume":"75","author":"JJ Liepnieks","year":"2010","unstructured":"Liepnieks\u00a0JJ, Zhang\u00a0LQ, Benson\u00a0MD (2010) Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 75(4):324\u2013327","journal-title":"Neurology"},{"issue":"1","key":"1570_CR40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13506129.2014.989318","volume":"22","author":"JM Beirao","year":"2015","unstructured":"Beirao\u00a0JM et\u00a0al (2015) Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid 22(1):31\u201335","journal-title":"Amyloid"},{"issue":"2","key":"1570_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jnnp-2014-308576","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima\u00a0Y (2015) Transthyretin-type cerebral amyloid angiopathy: a\u00a0serious complication in post-transplant patients with familial amyloid polyneuropathy. J\u00a0Neurol Neurosurg Psychiatry 86(2):124","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1570_CR42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"LF Maia","year":"2015","unstructured":"Maia\u00a0LF et\u00a0al (2015) CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J\u00a0Neurol Neurosurg Psychiatry 86(2):159\u2013167","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1570_CR43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando\u00a0Y et\u00a0al (2022) Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 29(3):143\u2013155","journal-title":"Amyloid"},{"issue":"1","key":"1570_CR44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1056\/NEJMe1805499","volume":"379","author":"JN Buxbaum","year":"2018","unstructured":"Buxbaum\u00a0JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N\u00a0Engl J Med 379(1):82\u201385","journal-title":"N Engl J Med"},{"issue":"3","key":"1570_CR45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici\u00a0L et al (2020) Quality of life outcomes in APOLLO, the phase\u00a03\u00a0trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid 27(3):153\u2013162","journal-title":"Amyloid"},{"issue":"4","key":"1570_CR46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD et al (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"key":"1570_CR47","doi-asserted-by":"publisher","unstructured":"Schmidt HH et al (2022) Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. https:\/\/doi.org\/10.1111\/ajt.17009","DOI":"10.1111\/ajt.17009"},{"key":"1570_CR48","doi-asserted-by":"publisher","unstructured":"Adams D et al (2022) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a\u00a0randomized clinical trial. Amyloid. https:\/\/doi.org\/10.1080\/13506129.2022.2091985","DOI":"10.1080\/13506129.2022.2091985"},{"key":"1570_CR49","unstructured":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04153149. Zugegriffen: 30. Juni 2023"},{"issue":"4","key":"1570_CR50","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00415-019-09671-9","volume":"267","author":"T Coelho","year":"2020","unstructured":"Coelho\u00a0T et\u00a0al (2020) Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J\u00a0Neurol 267(4):1070\u20131079","journal-title":"J Neurol"},{"issue":"1","key":"1570_CR51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta\u00a0NR et\u00a0al (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27(1):52\u201358","journal-title":"Amyloid"},{"issue":"1","key":"1570_CR52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","volume":"10","author":"T Coelho","year":"2021","unstructured":"Coelho\u00a0T et al (2021) Design and rationale of the global phase\u00a03 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther 10(1):375\u2013389","journal-title":"Neurol Ther"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01570-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:03:12Z","timestamp":1692806592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01570-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01570-6","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"17 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.F.\u00a0Pernice hat Personenf\u00f6rderung, Reisezusch\u00fcsse f\u00fcr wissenschaftliche Veranstaltungen und Rednerhonorare durch Alnylam Pharmaceuticals Inc, und pers\u00f6nliche F\u00f6rderung durch die Deutsche Gesellschaft f\u00fcr Muskelkranke (DGM) GmbH erhalten. K.\u00a0Hahn hat finanzielle Verg\u00fctung f\u00fcr Beratung, Advisory Board T\u00e4tigkeiten, Redner-\/Kongressbeitr\u00e4ge und Reisezusch\u00fcsse f\u00fcr wissenschaftliche Veranstaltungen von Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. und Swedish Orphan Biovitrum Inc, sowie Forschungsf\u00f6rderung von der Charit\u00e9 (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}